197 related articles for article (PubMed ID: 30362666)
1. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.
Castellsagué E; Li R; Aligue R; González S; Sanz J; Martin E; Velasco À; Capellá G; Stewart CJR; Vidal A; Majewski J; Rivera B; Polak P; Matias-Guiu X; Brunet J; Foulkes WD
Hum Mutat; 2019 Jan; 40(1):36-41. PubMed ID: 30362666
[TBL] [Abstract][Full Text] [Related]
2. Di-genic inheritance of germline POLE and PMS2 pathogenic variants causes a unique condition associated with pediatric cancer predisposition.
Michaeli O; Ladany H; Erez A; Ben Shachar S; Izraeli S; Lidzbarsky G; Basel-Salmon L; Biskup S; Maruvka YE; Toledano H; Goldberg Y
Clin Genet; 2022 Apr; 101(4):442-447. PubMed ID: 34967012
[TBL] [Abstract][Full Text] [Related]
3. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.
Vande Perre P; Siegfried A; Corsini C; Bonnet D; Toulas C; Hamzaoui N; Selves J; Chipoulet E; Hoffmann JS; Uro-Coste E; Guimbaud R
Fam Cancer; 2019 Apr; 18(2):173-178. PubMed ID: 30368636
[TBL] [Abstract][Full Text] [Related]
4. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
[TBL] [Abstract][Full Text] [Related]
5. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
6. Germline
Lindsay H; Scollon S; Reuther J; Voicu H; Rednam SP; Lin FY; Fisher KE; Chintagumpala M; Adesina AM; Parsons DW; Plon SE; Roy A
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31624068
[TBL] [Abstract][Full Text] [Related]
7. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
[TBL] [Abstract][Full Text] [Related]
8. Role of POLE and POLD1 in familial cancer.
Mur P; García-Mulero S; Del Valle J; Magraner-Pardo L; Vidal A; Pineda M; Cinnirella G; Martín-Ramos E; Pons T; López-Doriga A; Belhadj S; Feliubadaló L; Munoz-Torres PM; Navarro M; Grau E; Darder E; Llort G; Sanz J; Ramón Y Cajal T; Balmana J; Brunet J; Moreno V; Piulats JM; Matías-Guiu X; Sanz-Pamplona R; Aligué R; Capellá G; Lázaro C; Valle L
Genet Med; 2020 Dec; 22(12):2089-2100. PubMed ID: 32792570
[TBL] [Abstract][Full Text] [Related]
9. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas.
Spier I; Holzapfel S; Altmüller J; Zhao B; Horpaopan S; Vogt S; Chen S; Morak M; Raeder S; Kayser K; Stienen D; Adam R; Nürnberg P; Plotz G; Holinski-Feder E; Lifton RP; Thiele H; Hoffmann P; Steinke V; Aretz S
Int J Cancer; 2015 Jul; 137(2):320-31. PubMed ID: 25529843
[TBL] [Abstract][Full Text] [Related]
10. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management.
Palles C; Martin L; Domingo E; Chegwidden L; McGuire J; Cuthill V; Heitzer E; ; Kerr R; Kerr D; Kearsey S; Clark SK; Tomlinson I; Latchford A
Fam Cancer; 2022 Apr; 21(2):197-209. PubMed ID: 33948826
[TBL] [Abstract][Full Text] [Related]
11. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
12. Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient.
Yamaguchi K; Shimizu E; Yamaguchi R; Imoto S; Komura M; Hatakeyama S; Noguchi R; Takane K; Ikenoue T; Gohda Y; Yano H; Miyano S; Furukawa Y
J Hum Genet; 2019 Aug; 64(8):729-740. PubMed ID: 31089268
[TBL] [Abstract][Full Text] [Related]
13. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
[TBL] [Abstract][Full Text] [Related]
14. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1.
Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK
Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.
Palles C; Cazier JB; Howarth KM; Domingo E; Jones AM; Broderick P; Kemp Z; Spain SL; Guarino E; Salguero I; Sherborne A; Chubb D; Carvajal-Carmona LG; Ma Y; Kaur K; Dobbins S; Barclay E; Gorman M; Martin L; Kovac MB; Humphray S; ; ; Lucassen A; Holmes CC; Bentley D; Donnelly P; Taylor J; Petridis C; Roylance R; Sawyer EJ; Kerr DJ; Clark S; Grimes J; Kearsey SE; Thomas HJ; McVean G; Houlston RS; Tomlinson I
Nat Genet; 2013 Feb; 45(2):136-44. PubMed ID: 23263490
[TBL] [Abstract][Full Text] [Related]
16. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
17. POLE somatic mutations in advanced colorectal cancer.
Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
[TBL] [Abstract][Full Text] [Related]
18. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
[TBL] [Abstract][Full Text] [Related]
19. POLE mutations in families predisposed to cutaneous melanoma.
Aoude LG; Heitzer E; Johansson P; Gartside M; Wadt K; Pritchard AL; Palmer JM; Symmons J; Gerdes AM; Montgomery GW; Martin NG; Tomlinson I; Kearsey S; Hayward NK
Fam Cancer; 2015 Dec; 14(4):621-8. PubMed ID: 26251183
[TBL] [Abstract][Full Text] [Related]
20. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]